MRVI1 CRISPR/Cas9 KO Plasmid (h): sc-411458
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MRVI1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MRVI1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MRVI1 CRISPR/Cas9 KO Plasmid (h) | sc-411458 | 20 µg | $397.00 |
Overview
MRVI1 (murine retrovirus integration site 1 homolog) encodes a cytoplasmic scaffold protein that couples nitric oxide/cGMP signaling to intracellular calcium regulation, particularly through interaction with ITPR1 and modulation of IP3 receptor–dependent Ca2+ release. It participates in the PKG pathway and contributes to smooth muscle relaxation, platelet function, and broader control of Ca2+-driven signaling dynamics. MRVI1-dependent signaling impacts cellular processes such as contraction, secretion, and excitability by tuning second-messenger integration at the endoplasmic reticulum. Dysregulation of MRVI1-associated Ca2+ and cGMP pathways has been implicated in cardiovascular and hematologic phenotypes and is relevant to mechanistic studies of signaling alterations observed in cancer and other complex diseases.
MRVI1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MRVI1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MRVI1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MRVI1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MRVI1 protein expression.
This CRISPR knockout system enables efficient generation of MRVI1-deficient cell models for investigation of MRVI1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MRVI1 exon(s) critical for MRVI1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MRVI1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MRVI1 CRISPR/Cas9 KO Plasmid (h) and MRVI1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MRVI1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MRVI1 HDR Plasmid (h) and MRVI1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MRVI1 homology arms to support homology-directed repair at defined MRVI1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.